Commentary

Podcast

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

The PALOMA-3 trial showed subcutaneous amivantamab was better than IV among lung cancer patients.

This month, we spoke with Natasha B. Leighl, BSc, MMSc, MD, Medical Oncologist at the Princess Margaret Cancer Centre in Toronto, Canada. Leighl discussed the PALOMA-3 trial results, shared at the American Society of Clinical Oncology 2024 Conference. Leighl noted that the trial compared subcutaneous and intravenous administration of amivantamab for lung cancer.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Asthma COPD Breath Nebulizer And Mask Given By Doctor Or Nurse - Image credit: Angelov | stock.adobe.com
Psychiatric pharmacist and patient -- Image credit: NanSan | stock.adobe.com
Psychiatric pharmacist -- Image credit: HBS | stock.adobe.com
Hematology -- Image credit: DIgilife | stock.adobe.com
Image credit: Artur | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Related Content
Diffuse large B cell lymphoma (DLBCL) -- Image credit: SuriyaPhoto | stock.adobe.com
July 18th 2025

FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL

Gillian McGovern, Associate Editor
COBRRA Trial Results Raise Questions About VTE Management
July 15th 2025

COBRRA Trial Results Raise Questions About VTE Management

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
NCCN Flash Update: Updated CML Guidelines Emphasize Distress Screening, Drug Interactions, and Cost
July 18th 2025

NCCN Flash Update: Updated CML Guidelines Emphasize Distress Screening, Drug Interactions, and Cost

Alana Hippensteele, Lead Editor
Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike
July 10th 2025

Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike

Gustavo Alva, MD Luke Halpern, Assistant Editor
NCCN Flash Update: Ovarian Cancer Guidelines Version 3.2025 Released With Maintenance Therapy Adjustment for HR-Deficiency
July 18th 2025

NCCN Flash Update: Ovarian Cancer Guidelines Version 3.2025 Released With Maintenance Therapy Adjustment for HR-Deficiency

Alana Hippensteele, Lead Editor
Study Highlights Filgrastim Savings Potential With Biosimilars
July 18th 2025

Study Highlights Filgrastim Savings Potential With Biosimilars

Ethan Nolin-Halpern, PharmD Candidate